16 completed, 3 withdrawn, 2 terminated, 1 active not recruiting. 16 Phase 1, 10 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 13, Terminated 2, Withdrawn 1 |
| Phase 2 | 10 | Completed 4, Withdrawn 3, Active not recruiting 1, Recruiting 1, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow ImmunoGen, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors IMGC936 - Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | ImmunoGen, Inc. | 56 | 2020-10-29 | 2025-01-15 |
| A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Mirvetuximab Soravtansine - Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Completed | ImmunoGen, Inc. | 106 | 2020-07-23 | 2024-08-07 |
| Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer IMGN853 - Endometrial Cancer | Phase 2 | Recruiting | Alessandro Santin | 50 | 2020-07-15 | 2026-06-26 |
| A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) Pembrolizumab, IMGN853 - Endometrial Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 18 | 2020-01-02 | 2026-06-01 |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Mirvetuximab Soravtansine, Bevacizumab - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Withdrawn | University of Oklahoma | 2019-05-31 | 2019-06-27 | |
| Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study - BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 25 | 2018-07-12 | 2025-02-13 |
| Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343) - Neoplasms | Phase 1 | Completed | Bayer | 173 | 2017-05-26 | 2022-06-30 |
| A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 3 | Completed | ImmunoGen, Inc. | 366 | 2016-03-02 | 2020-10-14 |
| Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer Mirvetuximab soravtansine, Bevacizumab, Carboplatin - Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 1 / Phase 2 | Completed | ImmunoGen, Inc. | 264 | 2016-03-02 | 2024-06-14 |
| Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia IMGN779 - Acute Myeloid Leukemia | Phase 1 | Completed | ImmunoGen, Inc. | 62 | 2016-03-01 | 2019-09-04 |
| An Open-label Phase II Study of Lorvotuzumab Mertansine Lorvotuzumab Mertansine (IMGN901) - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 9 | 2015-05-12 | 2018-08-28 |
| A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors IMGN289 - EGFR Positive Solid Tumors | Phase 1 | Terminated | ImmunoGen, Inc. | 20 | 2013-10-01 | 2015-10-02 |
| First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Mirvetuximab soravtansine - Tumors | Phase 1 | Completed | ImmunoGen, Inc. | 206 | 2012-06-28 | 2021-02-17 |
| IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia IMGN529 - Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia | Phase 1 | Completed | ImmunoGen, Inc. | 49 | 2012-01-01 | 2017-12-29 |
| A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer IMGN901, Carboplatin and Etoposide - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | ImmunoGen, Inc. | 181 | 2010-11-01 | 2018-01-18 |
| IMGN901 in Combination With Lenalidomide and Dexamethasone IMGN901 - Multiple Myeloma | Phase 1 | Completed | ImmunoGen, Inc. | 50 | 2009-12-01 | 2014-11-21 |
| A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors IMGN388 - Solid Tumor | Phase 1 | Completed | ImmunoGen, Inc. | 60 | 2008-06-01 | 2013-09-13 |
| huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas huC242-DM4 - Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer | Phase 2 | Withdrawn | ImmunoGen, Inc. | 2007-05-01 | 2015-08-26 | |
| BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma BB-10901 - Multiple Myeloma | Phase 1 | Completed | ImmunoGen, Inc. | 37 | 2005-04-01 | 2013-04-23 |
Showing 20 of 23. Sign in to see all of them.
Fallopian Tube Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Endometrial Neoplasms (3) · Leukemia, Myeloid, Acute (3) · Ovarian Neoplasms (3) · Small Cell Lung Carcinoma (3) · Multiple Myeloma (2) · Neoplasms (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Squamous Cell (1)
mirvetuximab soravtansine (8) · lorvotuzumab mertansine (6) · Bevacizumab (2) · Carboplatin (2) · liposomal doxorubicin (2) · pembrolizumab (2) · Ado-Trastuzumab Emtansine (1) · Biopsy (1) · CPX-351 (1) · Cisplatin (1) · Cytarabine (1) · Daunorubicin (1) · Etoposide (1) · Gemcitabine (1) · Hydrocortisone (1)
United States (22) · Spain (6) · Canada (5) · Belgium (4) · Italy (4) · United Kingdom (4) · Switzerland (3) · Australia (2) · Czechia (2) · France (2) · Ireland (2) · Argentina (1) · Bosnia and Herzegovina (1) · Bulgaria (1) · Germany (1)
Alain Mita, MD (1) · Alessandro D. Santin, M.D. (1) · Andrea Vergara-Silva, MD (1) · Asher Alban Akmal Chanan-Khan,, M.D. (1) · Floor Backes, MD (1) · Matthew A Kutny (1) · Michael Method, MD, MPH, MBA (1) · Naval Daver, MD (1) · Patrick Zweidler-McKay, MD (1) · Paul C. Lorigan, MD (1) · Rebecca Porter, MD, PhD (1) · Robert Coleman, MD (1) · Ursula Matulonis, MD (1)
PMID 33667670, PMID 35511740, PMID 36716407, PMID 37212825, PMID 38182653, PMID 38858103, PMID 40700855
2016 (1), U10CA180886 (1)